BHCM
CADL icon

Brevan Howard Capital Management’s Candel Therapeutics CADL Stock Holding History

Brevan Howard Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.9K Buy
+11,821
New +$64.3K ﹤0.01% 2075

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's CADL Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 11,821 shares worth $57.9K. The stake represents ﹤0.01% of the portfolio and ranks #2075 among its holdings.

114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Brevan Howard Capital Management held 11,821 shares of Candel Therapeutics worth $57.9K as of Q1 2026.
  • Candel Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2075 holding.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.